MétaCan
Menu
Back to cohort
Record W4416771546 · doi:10.1007/s12254-025-01087-8

EGFR-mutated advanced non-small cell lung cancer: new era of systemic therapy towards new standards of care

2025· article· en· W4416771546 on OpenAlexaff
Oliver Illini

Bibliographic record

Venuememo - Magazine of European Medical Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsCARE Canada
Fundersnot available
KeywordsOsimertinibClinical trialLung cancerChemotherapyStandard of careSystemic therapy

Abstract

fetched live from OpenAlex

This review summarizes current systemic treatment strategies for advanced EGFR-mutated non-small cell lung cancer (NSCLC), with a focus on novel first-line regimens and emerging concepts beyond progression. Evidence from pivotal phase III trials and recent regulatory developments was analyzed, emphasizing efficacy outcomes, safety profiles, and patient selection factors relevant for routine clinical practice. Osimertinib has long been the standard first-line therapy, yet resistance inevitably emerges. The two novel combination strategies, osimertinib plus platinum–pemetrexed chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA), have shown superior progression-free and overall survival compared with osimertinib monotherapy. These regimens are associated with higher toxicity, treatment burden, and costs, requiring careful patient selection based on comorbidities, risk features, and preferences. After progression, treatment options remain limited. Current postprogression data are almost exclusively derived from patients previously treated with first-line osimertinib monotherapy, and it remains unclear how outcomes will evolve following upfront combination regimens. Platinum-based chemotherapy remains the historical backbone, while continuation of EGFR inhibition with targeted agents or chemotherapy (e.g., MARIPOSA‑2, COMPEL) and the development of antibody–drug conjugates such as datopotamab deruxtecan represent promising strategies, especially in view of the rapidly changing first-line landscape. Upfront combination regimens have redefined the standard of care in EGFR-mutated advanced NSCLC, but their survival benefit must be weighed against added toxicity, logistical complexity, and financial impact. Expanding therapeutic options make individualized shared decision-making essential to balance efficacy, tolerability, logistics, and patient priorities, aiming to maintain quality of life while extending survival.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0010.002
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.352
Teacher spread0.343 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venuememo - Magazine of European Medical OncologySame topicLung Cancer Treatments and MutationsFrench-language works237,207